GlobeNewswire: Jounce Therapeutics, Inc. Contains the last 10 of 148 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T01:56:56ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2023/05/04/2660993/0/en/Jounce-Therapeutics-Announces-Closing-of-Tender-Offer.html?f=22&fvtc=4&fvtv=28111Jounce Therapeutics Announces Closing of Tender Offer2023-05-04T00:35:17Z<![CDATA[Stockholders to Receive $1.85 Per Share in Cash Plus Contingent Value Rights Stockholders to Receive $1.85 Per Share in Cash Plus Contingent Value Rights]]>https://www.globenewswire.com/news-release/2023/04/03/2639214/0/en/Termination-of-Proposed-Business-Combination-of-Jounce-Therapeutics-Inc-and-Redx-Pharma-plc.html?f=22&fvtc=4&fvtv=28111Termination of Proposed Business Combination of Jounce Therapeutics, Inc. and Redx Pharma plc2023-04-03T06:00:00Z<![CDATA[NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.]]>https://www.globenewswire.com/news-release/2023/03/27/2634797/0/en/Jounce-Therapeutics-Enters-Into-Agreement-to-Be-Acquired-by-Concentra-Biosciences-for-1-85-in-Cash-per-Share-Plus-Contingent-Value-Rights.html?f=22&fvtc=4&fvtv=28111Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value Rights2023-03-27T13:00:00Z<![CDATA[NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.]]>https://www.globenewswire.com/news-release/2023/03/16/2629209/0/en/Jounce-Therapeutics-Announces-Results-from-Pre-Planned-Data-Review-of-INNATE-Phase-2-Trial-of-JTX-8064-and-Pimivalimab-Demonstrating-Deep-and-Durable-Responses-in-Platinum-Resistan.html?f=22&fvtc=4&fvtv=28111Jounce Therapeutics Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrating Deep and Durable Responses in Platinum Resistant Ovarian Cancer2023-03-16T20:30:00Z<![CDATA[CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that patients from the INNATE Phase 2 trial in the ovarian cancer combination cohort with platinum resistant ovarian cancer are experiencing deep and durable responses based on a pre-planned informal data review.]]>Ovarian Combination Cohort Target Lesion % Change from Baseline over TimeOvarian Combination Cohort Target Lesion % Change from Baseline over Timehttps://www.globenewswire.com/news-release/2023/03/15/2627320/0/en/Jounce-Therapeutics-Confirms-Receipt-of-Unsolicited-Proposal-from-Concentra-Biosciences.html?f=22&fvtc=4&fvtv=28111Jounce Therapeutics Confirms Receipt of Unsolicited Proposal from Concentra Biosciences2023-03-15T01:00:00Z<![CDATA[NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.]]>https://www.globenewswire.com/news-release/2023/02/23/2613916/0/en/Redx-and-Jounce-Announce-Recommended-Business-Combination.html?f=22&fvtc=4&fvtv=28111Redx and Jounce Announce Recommended Business Combination2023-02-23T07:30:00Z<![CDATA[Combined group will have a strong clinical pipeline and proven expertise in the discovery and development of highly selective therapeutics for the treatment of cancer and fibrotic disease]]>https://www.globenewswire.com/news-release/2023/02/22/2613789/0/en/Jounce-Therapeutics-Announces-Restructuring.html?f=22&fvtc=4&fvtv=28111Jounce Therapeutics Announces Restructuring2023-02-22T22:00:00Z<![CDATA[CAMBRIDGE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced today that it is reducing its workforce by approximately 57 percent. The decision to reduce its workforce was made as Jounce believes advancement of its clinical programs, JTX-8064 and vopratelimab, requires funding and a scope that the Company cannot pursue on its own and will be seeking business development opportunities for both programs.]]>https://www.globenewswire.com/news-release/2022/12/27/2580000/0/en/Gilead-To-Acquire-All-Remaining-Rights-To-Potential-First-In-Class-Immunotherapy-GS-1811-From-Jounce-Therapeutics.html?f=22&fvtc=4&fvtv=28111Gilead To Acquire All Remaining Rights To Potential First-In-Class Immunotherapy GS-1811 From Jounce Therapeutics2022-12-27T21:30:00Z<![CDATA[-- Agreement Covers Buyout of Remaining Financial Obligations for Anti-CCR8 Antibody in Development as a Potential Treatment for Solid Tumors -- -- Agreement Covers Buyout of Remaining Financial Obligations for Anti-CCR8 Antibody in Development as a Potential Treatment for Solid Tumors --]]>https://www.globenewswire.com/news-release/2022/12/08/2570163/0/en/Jounce-Therapeutics-Presents-INNATE-Phase-1-and-SELECT-Clinical-Trial-data-at-the-European-Society-of-Medical-Oncology-Immuno-Oncology-ESMO-IO-Annual-Congress.html?f=22&fvtc=4&fvtv=28111Jounce Therapeutics Presents INNATE Phase 1 and SELECT Clinical Trial data at the European Society of Medical Oncology Immuno-Oncology (ESMO - IO) Annual Congress2022-12-08T12:50:00Z<![CDATA[- INNATE trial Phase 1 dose escalation data showed JTX-8064 was well-tolerated as a single agent and in combination with pimivalimab (pimi) -]]>https://www.globenewswire.com/news-release/2022/11/10/2552967/0/en/Jounce-Therapeutics-Reports-Third-Quarter-2022-Financial-Results.html?f=22&fvtc=4&fvtv=28111Jounce Therapeutics Reports Third Quarter 2022 Financial Results2022-11-10T12:00:00Z<![CDATA[- INNATE trial of JTX-8064 +/- pimivalimab Phase 1 Dose Escalation data at ESMO-IO Annual Congress -]]>